Results 71 to 80 of about 7,245,224 (256)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

MOGA-Based Multi-drug Optimisation for Cancer Chemotherapy [PDF]

open access: yes, 2011
This paper presents a novel method of multi-drug scheduling using multi-objective genetic algorithm (MOGA) that can find suitable/optimum dosages by trading-off between cell killing and toxic side-effects of chemotherapy treatment.
Majumder, Azim   +9 more
core   +1 more source

Five-year trend of acquired antitubercular drug resistance in patients attending a tertiary care hospital at Dehradun (Uttarakhand)

open access: yesLung India, 2009
Background/Aim: To study the prevalence and trend of acquired drug resistance to the first line antitubercular drugs . Materials and Methods: Sputum of 215 previously treated adult pulmonary tuberculosis (TB) patients over a period of 2002-2006 were ...
Rawat Jagdish, Sindhwani G, Dua Ruchi
doaj  

Non-antibiotics, Efflux Pumps and Drug Resistance of Gram-negative Rods [PDF]

open access: yesPolish Journal of Microbiology, 2018
Non-antibiotic medicinal products consist of drugs with diverse activity against bacteria. Many non-antibiotics demonstrate direct anti-bacterial activity against Gram-positive cocci. The activity observed against Gram-negative rods is much lower and non-
AGNIESZKA EWA LAUDY
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Investigation of the role of LRP in multidrug resistance [PDF]

open access: yes, 1998
There have been many reports linking the overexpression of the lung resistance-related protein (LRP) with cross-resistance to chemotherapeutic drugs.
Byrne, Daragh
core   +2 more sources

Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease

open access: yesBiology, 2012
Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and ...
Ladislau C. Kovari   +6 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]

open access: yes, 2014
This work was supported by grants from Breakthrough Breast Cancer and Scottish Funding Council (SRDG), and personal support to Alexey Goltsov from Scottish Informatics and Computer Science Alliance (SICSA) and to James Bown from The Northwood Trust.Drug ...
Bown, James   +22 more
core   +1 more source

Home - About - Disclaimer - Privacy